NASDAQ:VTGN - Vistagen Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $1.38 +0.02 (+1.47 %) (As of 07/22/2018 08:51 AM ET)Previous Close$1.38Today's Range$1.35 - $1.4052-Week Range$0.69 - $2.65Volume99,045 shsAverage Volume250,842 shsMarket Capitalization$31.79 millionP/E RatioN/ADividend YieldN/ABeta0.29 Company ProfileFinancialsAnalyst RatingsEarnings HistoryHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California. Receive VTGN News and Ratings via Email Sign-up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:VTGN CUSIPN/A Webwww.vistagen.com Phone650-577-3600 Debt Debt-to-Equity RatioN/A Current Ratio7.60 Quick Ratio7.60 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.25 million Price / Sales25.44 Cash FlowN/A Price / CashN/A Book Value$0.30 per share Price / Book4.60 Profitability EPS (Most Recent Fiscal Year)($1.11) Net Income$-14,340,000.00 Net MarginsN/A Return on Equity-381.91% Return on Assets-186.07% Miscellaneous Employees9 Outstanding Shares23,040,000Market Cap$31.79 Vistagen Therapeutics (NASDAQ:VTGN) Frequently Asked Questions What is Vistagen Therapeutics' stock symbol? Vistagen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN." How were Vistagen Therapeutics' earnings last quarter? Vistagen Therapeutics Inc (NASDAQ:VTGN) posted its earnings results on Tuesday, June, 26th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.28) by $0.09. View Vistagen Therapeutics' Earnings History. What price target have analysts set for VTGN? 4 brokers have issued 12-month target prices for Vistagen Therapeutics' shares. Their predictions range from $6.00 to $22.00. On average, they anticipate Vistagen Therapeutics' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 624.6% from the stock's current price. View Analyst Ratings for Vistagen Therapeutics. What is the consensus analysts' recommendation for Vistagen Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vistagen Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Vistagen Therapeutics stock? Here are some recent quotes from research analysts about Vistagen Therapeutics stock: 1. Chardan Capital analysts commented, "We understand that trial centers are continuing to come online and patient enrollment is on track. Of note, also, is the anticipated data in 2H18 from the NIMH-sponsored 25-patient phase II trial (NCT02484456) of AV-101 as a monotherapy, which will likely provide helpful insight on biomarker and mechanistic data. To support the continued development of AV-101, VistaGen has been issued a patent on the therapeutic uses of AV-101 in MDD (similar to methods of use) as well as a patent on unit dose formulations (almost tantamount to composition of matter). The patents provide protection for AV-101 through 2034." (6/29/2018) 2. According to Zacks Investment Research, "VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California. " (4/7/2018) Who are some of Vistagen Therapeutics' key competitors? Some companies that are related to Vistagen Therapeutics include Adamis Pharmaceuticals (ADMP), MOTIF BIO PLC/S (MTFB), Catalyst Biosciences (CBIO), Steadymed (STDY), Leap Therapeutics (LPTX), Recro Pharma (REPH), Iterum Therapeutics (ITRM), Otonomy (OTIC), Affimed (AFMD), Alpine Immune Sciences (ALPN), Gemphire Therapeutics (GEMP), Aptevo Therapeutics (APVO), Zynerba Pharmaceuticals (ZYNE), Infinity Pharmaceuticals (INFI) and Aerpio Pharmaceuticals (ARPO). Who are Vistagen Therapeutics' key executives? Vistagen Therapeutics' management team includes the folowing people: Mr. Shawn K. Singh J.D., CEO & Director (Age 55)Dr. H. Ralph Snodgrass Ph.D., Founder, Pres, Chief Scientific Officer & Director (Age 68)Mr. Jerrold D. Dotson CPA, CFO, VP & Sec. (Age 65)Dr. Mark A. Smith M.D., Ph.D., Chief Medical Officer (Age 63)Mr. Mark Adrian McPartland, VP of Corp. Devel. (Age 52) Has Vistagen Therapeutics been receiving favorable news coverage? Media headlines about VTGN stock have trended somewhat positive this week, according to Accern. The research firm rates the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Vistagen Therapeutics earned a coverage optimism score of 0.18 on Accern's scale. They also gave media coverage about the company an impact score of 45.92 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. How do I buy shares of Vistagen Therapeutics? Shares of VTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Vistagen Therapeutics' stock price today? One share of VTGN stock can currently be purchased for approximately $1.38. How big of a company is Vistagen Therapeutics? Vistagen Therapeutics has a market capitalization of $31.79 million and generates $1.25 million in revenue each year. The company earns $-14,340,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis. Vistagen Therapeutics employs 9 workers across the globe. How can I contact Vistagen Therapeutics? Vistagen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-577-3600 or via email at [email protected] MarketBeat Community Rating for Vistagen Therapeutics (NASDAQ VTGN)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 117 (Vote Outperform)Underperform Votes: 82 (Vote Underperform)Total Votes: 199MarketBeat's community ratings are surveys of what our community members think about Vistagen Therapeutics and other stocks. Vote "Outperform" if you believe VTGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTGN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: Should I invest in "strong buy" stocks?